FBXL2 and non-small cell lung carcinoma: In addition, FBXL2 also markedly suppressed expression of EGFR E709K, L798I, and L844V, all of which were identified from NSCLC patients resistance to WZ4002 and CO1686, two potential 3rd-generation TKIs in preclinical studies38,39 (Supplementary Fig. 10a).